Hsuan-Ling Liao
Nurse Practitioner · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
Offices
1 location · Genesis Healthcare Partners PC · 232 clinicians in this group
Looking this up.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Hsuan-Ling Liao’s office at (408) 471-2222 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Original Medicare doctor bills
$14,734
Medicare paid this office $14,734 for 189 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 55 | $4,253 | $70 |
| Short return visit | 78 | $3,198 | $40 |
| New patient visit (15+ min) | 49 | $2,202 | $45 |
| Return visit (30+ min) | 22 | $2,170 | $90 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 56 | $799 | $12 |
Who their Medicare patients are
189 Original Medicare patients in 2024. Average age 73 · Under 65 11% · 85 and older 9% · Women 65% · Also on Medicaid 34% · Health risk score 1.03. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 42% · Depression 20% · Coronary heart disease 19% · Chronic kidney disease 19% · Cancer 14% · Heart failure 12% · COPD 11% · Atrial fibrillation 8%.
The office billed $100,535, Medicare allowed $21,396 and paid $14,734; for 302 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 189 | 302 | 73 | 1.03 | $100,535 | $14,734 |
| 2023 | 129 | 140 | 72 | 1.50 | $69,200 | $9,994 |
| 2022 | 16 | 16 | 70 | 1.06 | $5,185 | $1,187 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 34 | $3,463 | $94 |
| New patient visit (45+ min) | 13 | $1,739 | $134 |
| Short return visit (20+ min) | 30 | $1,630 | $53 |
| Short return visit | 26 | $1,070 | $41 |
| New patient visit (15+ min) | 12 | $580 | $48 |
Drugs they prescribed that Part D paid
$546,324
Pharmacies billed $546,324 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 935) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
684 generic and 251 brand-name prescriptions · $546,324 in drug cost · 77 antibiotic prescriptions to 42 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xifaxan | 43 | $119,280 | $2,774 |
| Creon | 26 | $97,324 | $3,743 |
| Vemlidy | 57 | $92,692 | $1,626 |
| Linzess | 18 | $18,547 | $1,030 |
| Tenofovir Disoproxil | 14 | $9,750 | $696 |
See all 22 drugs
| Xifaxan | 43 | $119,280 | $2,774 |
| Creon | 26 | $97,324 | $3,743 |
| Vemlidy | 57 | $92,692 | $1,626 |
| Linzess | 18 | $18,547 | $1,030 |
| Tenofovir Disoproxil | 14 | $9,750 | $696 |
| Entecavir | 34 | $6,885 | $203 |
| Ursodiol | 11 | $4,552 | $414 |
| Mesalamine Er | 12 | $3,866 | $322 |
| Mesalamine | 15 | $3,098 | $207 |
| Gavilyte-G | 96 | $1,375 | $14 |
| Sod Sulf-Potass Sulf-Mag Sulf | 19 | $1,244 | $65 |
| Omeprazole | 112 | $1,158 | $10 |
| Lactulose | 20 | $1,090 | $54 |
| Pantoprazole | 76 | $987 | $13 |
| Famotidine | 40 | $819 | $20 |
| Peg-3350 and Electrolytes | 49 | $696 | $14 |
| Sucralfate | 19 | $535 | $28 |
| Dicyclomine | 31 | $522 | $17 |
| Peg 3350-Electrolyte | 27 | $487 | $18 |
| Hydrocortisone | 23 | $379 | $16 |
| Lansoprazole | 11 | $242 | $22 |
| Furosemide | 14 | $107 | $8 |
Year by year
| 2024 | 935 | 403 | 0% (0) | 27% | $546,324 |
| 2023 | 980 | 421 | 0% (0) | None | $485,922 |
| 2022 | 442 | 215 | 0% (0) | 28% | $222,949 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Xifaxan | 53 | $159,536 | $3,010 |
| Vemlidy | 75 | $108,078 | $1,441 |
| Creon | 24 | $79,572 | $3,315 |
| Linzess | 16 | $16,535 | $1,033 |
| Mesalamine | 20 | $9,996 | $500 |
| Entecavir | 26 | $7,679 | $295 |
| Gavilyte-G | 154 | $2,713 | $18 |
| Sutab | 16 | $2,700 | $169 |
| Lactulose | 38 | $2,029 | $53 |
| Omeprazole | 104 | $1,934 | $19 |
| Dicyclomine | 73 | $1,813 | $25 |
| Pantoprazole | 65 | $1,706 | $26 |
| Sod Sulf-Potass Sulf-Mag Sulf | 15 | $1,177 | $78 |
| Hydrocortisone | 24 | $1,131 | $47 |
| Lansoprazole | 12 | $884 | $74 |
| Famotidine | 33 | $629 | $19 |
| Peg-3350 and Electrolytes | 23 | $489 | $21 |
| Spironolactone | 14 | $468 | $33 |
| Peg 3350-Electrolyte | 11 | $286 | $26 |
| Gavilyte-C | 11 | $228 | $21 |
| Furosemide | 18 | $108 | $6 |
2022: 12 drugs
| Xifaxan | 14 | $36,217 | $2,587 |
| Creon | 11 | $23,736 | $2,158 |
| Vemlidy | 11 | $14,254 | $1,296 |
| Mesalamine | 27 | $7,128 | $264 |
| Sutab | 17 | $2,690 | $158 |
| Dicyclomine | 50 | $1,223 | $24 |
| Omeprazole | 47 | $786 | $17 |
| Gavilyte-G | 41 | $605 | $15 |
| Peg-3350 and Electrolytes | 27 | $385 | $14 |
| Pantoprazole | 28 | $384 | $14 |
| Lactulose | 12 | $290 | $24 |
| Famotidine | 15 | $122 | $8 |
Money from drug and device companies
$1,694 in 2025
| 2025 | 15 | 80 | None | $1,694 |
| 2024 | 13 | 85 | None | $1,467 |
| 2023 | 17 | 83 | None | $1,518 |
| 2022 | 8 | 46 | None | $804 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $476 | 28 payments
|
| Gilead Sciences | Livdelzi | $284 | 13 payments
|
| Janssen Biotech | Tremfya | $227 | 9 payments
|
| Ardelyx | Ibsrela | $112 | 5 payments
|
| Celltrion USA | Vegzelma | $98 | 5 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $92 | 4 payments
|
See all 80 published payments
| Janssen Biotech | Meals · 2025-12-29 | Tremfya | $28 |
| Ardelyx | Meals · 2025-12-03 | Ibsrela | $22 |
| Celltrion USA | Meals · 2025-11-18 | Vegzelma | $20 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-11-10 | Xifaxan | $22 |
| Abbvie | Meals · 2025-11-06 | Creon | $8 |
| Ardelyx | Meals · 2025-11-06 | Ibsrela | $17 |
| Abbvie | Meals · 2025-10-30 | Creon | $25 |
| Recordati Rare Diseases Inc. | Meals · 2025-10-28 | Panhematin | $29 |
| Abbvie | Meals · 2025-10-22 | Creon | $9 |
| Abbvie | Meals · 2025-10-21 | Skyrizi | $24 |
| Gilead Sciences | Meals · 2025-10-08 | None | $7 |
| Janssen Biotech | Meals · 2025-10-01 | Tremfya | $8 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-09-22 | Xifaxan | $16 |
| Abbvie | Meals · 2025-08-28 | Viberzi | $25 |
| Abbvie | Meals · 2025-08-13 | Rinvoq | $25 |
| Abbvie | Meals · 2025-08-08 | Linzess | $20 |
| Abbvie | Meals · 2025-07-31 | Viberzi | $6 |
| Celltrion USA | Meals · 2025-07-31 | Vegzelma | $24 |
| Abbvie | Meals · 2025-07-30 | Rinvoq | $23 |
| Gilead Sciences | Meals · 2025-07-24 | None | $9 |
| Janssen Biotech | Education · 2025-07-17 | Tremfya | $84 |
| Janssen Biotech | Meals · 2025-07-15 | Tremfya | $27 |
| Abbvie | Meals · 2025-07-14 | Skyrizi | $24 |
| Abbvie | Meals · 2025-07-09 | Rinvoq | $26 |
| Pfizer | Meals · 2025-06-24 | Xeljanz | $16 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-06-23 | Entyvio | $23 |
| Gilead Sciences | Meals · 2025-06-19 | None | $26 |
| Ardelyx | Meals · 2025-06-18 | Ibsrela | $16 |
| Abbvie | Meals · 2025-06-13 | Linzess | $15 |
| Janssen Biotech | Meals · 2025-06-10 | Tremfya | $19 |
| Ardelyx | Meals · 2025-06-09 | Ibsrela | $29 |
| Abbvie | Meals · 2025-06-06 | Linzess | $7 |
| Abbvie | Meals · 2025-06-05 | Linzess | $1 |
| Celltrion USA | Meals · 2025-06-05 | Vegzelma | $16 |
| Braintree Laboratories | Meals · 2025-06-03 | Sutab | $45 |
| Gilead Sciences | Meals · 2025-06-03 | None | $8 |
| Fresenius Kabi USA | Meals · 2025-05-29 | Adalimumab-Aacf | $35 |
| Madrigal Pharmaceuticals | Meals · 2025-05-27 | Rezdiffra | $22 |
| Intercept Pharmaceuticals | Meals · 2025-05-15 | Ocaliva | $30 |
| Vivus | Meals · 2025-05-06 | Pancreaze | $24 |
| Abbvie | Meals · 2025-05-06 | Linzess | $12 |
| Abbvie | Meals · 2025-05-05 | Rinvoq | $24 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-05-01 | Entyvio | $19 |
| Janssen Biotech | Meals · 2025-04-30 | Tremfya | $20 |
| Gilead Sciences | Meals · 2025-04-30 | None | $25 |
| Intercept Pharmaceuticals | Meals · 2025-04-28 | Ocaliva | $22 |
| Abbvie | Meals · 2025-04-22 | Skyrizi | $23 |
| Abbvie | Meals · 2025-04-17 | Linzess | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-16 | Entyvio | $27 |
| Abbvie | Meals · 2025-04-08 | Linzess | $11 |
| Gilead Sciences | Meals · 2025-04-08 | None | $10 |
| Celltrion USA | Meals · 2025-04-08 | Vegzelma | $19 |
| Vivus | Meals · 2025-04-03 | Pancreaze | $25 |
| Abbvie | Meals · 2025-03-27 | Rinvoq | $13 |
| Gilead Sciences | Meals · 2025-03-24 | None | $10 |
| Gilead Sciences | Meals · 2025-03-18 | None | $11 |
| Abbvie | Meals · 2025-03-15 | Linzess | $7 |
| Abbvie | Meals · 2025-03-12 | Rinvoq | $26 |
| Ardelyx | Meals · 2025-03-10 | Ibsrela | $29 |
| Janssen Biotech | Meals · 2025-03-06 | Tremfya | $10 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-05 | Entyvio | $22 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $6 |
| Abbvie | Meals · 2025-02-25 | Linzess | $12 |
| Novo Nordisk | Meals · 2025-02-24 | Wegovy | $31 |
| Gilead Sciences | Meals · 2025-02-21 | None | $6 |
| Gilead Sciences | Meals · 2025-02-19 | None | $27 |
| Gilead Sciences | Meals · 2025-02-19 | None | $6 |
| Pfizer | Meals · 2025-02-12 | Xeljanz | $16 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-12 | Xifaxan | $21 |
| Abbvie | Meals · 2025-02-06 | Linzess | $15 |
| Abbvie | Meals · 2025-02-06 | Rinvoq | $27 |
| Abbvie | Meals · 2025-02-04 | Creon | $25 |
| Gilead Sciences | Meals · 2025-02-03 | None | $8 |
| Braintree Laboratories | Meals · 2025-01-30 | Sutab | $23 |
| Janssen Biotech | Meals · 2025-01-28 | Tremfya | $25 |
| Abbvie | Meals · 2025-01-27 | Linzess | $7 |
| Gilead Sciences | Meals · 2025-01-24 | Livdelzi | $131 |
| Abbvie | Meals · 2025-01-23 | Linzess | $14 |
| Celltrion USA | Meals · 2025-01-22 | Vegzelma | $20 |
| Madrigal Pharmaceuticals | Meals · 2025-01-08 | Rezdiffra | $25 |
See earlier years (2024, 2023, 2022)
2024: $1,467
| Abbvie | Rinvoq | $497 | 29 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $278 | 23 payments
|
| Gilead Sciences | None | $181 | 10 payments
|
| Celltrion USA | Vegzelma | $102 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $73 | 4 payments
|
| Pfizer | Xeljanz | $70 | 3 payments
|
| Braintree Laboratories | Suflave | $54 | 3 payments
|
| Ipsen Biopharmaceuticals | Iqirvo | $49 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $45 | 2 payments
|
| Janssen Biotech | Stelara | $44 | 2 payments
|
| Phathom Pharmaceuticals | Voquezna | $29 | 1 payment
|
| Lilly USA | Omvoh | $27 | 1 payment
|
| QOL Medical | Sucraid | $17 | 1 payment
|
2023: $1,518
| Abbvie | Rinvoq | $430 | 31 payments
|
| Gilead Sciences | Vemlidy | $328 | 10 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $190 | 18 payments
|
| Nestle Healthcare Nutrition | Zenpep | $92 | 3 payments
|
| Novo Nordisk | Wegovy | $62 | 3 payments
|
| Aimmune Therapeutics | Vowst | $61 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $54 | 3 payments
|
| Ardelyx | Ibsrela | $53 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $52 | 2 payments
|
| RedHill Biopharma | Talicia | $31 | 2 payments
|
| Celltrion USA | Yuflyma | $29 | 1 payment
|
| Celgene | Zeposia | $29 | 1 payment
|
| Janssen Biotech | Stelara | $28 | 1 payment
|
| Vivus | Pancreaze | $24 | 1 payment
|
| Braintree Laboratories | Suflave | $23 | 1 payment
|
| Lilly USA | None | $18 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $14 | 1 payment
|
2022: $804
| Abbvie | Skyrizi | $250 | 16 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $213 | 17 payments
|
| Gilead Sciences | Vemlidy | $131 | 8 payments
|
| Janssen Scientific Affairs | Stelara | $125 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $25 | 1 payment
|
| Novo Nordisk | Saxenda | $25 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $22 | 1 payment
|
| RedHill Biopharma | Talicia | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1548914591
- Licence
- CA 95019981, CA 95265764
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LA2100X (363LA2100X); Federal specialty code 163W00000X (163W00000X)
- Mailing address
- 200 Jose Figueres Ave Ste 170, San Jose, CA, 95116
- NPI first listed
- 2022-02-08
- NPI last updated
- 2023-08-28
- NPI record certified
- 2023-08-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 14901 National Ave Ste 101, Los Gatos, CA, 95032